Our previous study demonstrated that HSF2 deficiency accelerated disease progression and shortened lifespan in a mouse model of Huntington’s disease, suggesting that HSF2 could be a potential therapeutic target for neurodegenerative diseases by regulating the expression of αB-crystallin (CRYAB) (Shinkawa et al., 2011). This evidence concerns the gene CRYAB and Huntington disease.